Aurenar raises $5.7M to advance stroke neuromodulation device
Summary
Aurenar closed an oversubscribed $5.7 million seed round led by the American Heart Association’s Go Red for Women Venture Fund and Solas BioVentures to advance its V-Link non-invasive transauricular vagus nerve stimulation platform. The device, which holds FDA Breakthrough Device designation, targets reduction of cerebral vasospasm after aneurysmal subarachnoid hemorrhage in ICU patients. Funds will complete development, verification testing, regulatory submissions, and preparation for a pivotal trial.
Why it matters
Aurenar's $5.7M seed funds development of a non-invasive ear-worn vagus nerve stimulator targeting inflammation-driven complications in ICU patients, a large and costly patient population with few targeted treatments. The WashU spinout's FDA Breakthrough Device designation signals a faster potential path to clinical use.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial